Bayer: business at prior-year level – on track with strategy

  • Group sales €35.0 billion (Fx & portfolio adj. +1.5%)
  • Another record year for Pharmaceuticals
  • Weak business development at Consumer Health
  • Crop Science business down against prior year due to situation in Brazil – measures taking effect
  • EBITDA before special items €9.3 billion (−0.3%)
  • Net income €7.3 billion (+61.9%)
  • Core earnings per share €6.74 (+1.0%)
  • Covestro deconsolidated – additional cash inflows of €4.7 billion
  • Monsanto acquisition expected to close in second quarter of 2018
  • Further progress in implementing sustainability targets
  • Group outlook for 2018: increase in sales (Fx & portfolio adj.), EBITDA before special items and core earnings per share (Fx adj.) at prior-year level due to currency effects

Sales 1

+ 1.5 %

EBITDA Before Special Items

- 0.3 %

Net Income 2

+ 61.9 %

Core Earnings per Share 2

+ 1.0 %

Supplier Management

99.5 % of all strategically important suppliers evaluated since 2012

Investment in Research and Development

4.5 billion

Specific Greenhouse Gas Emissions2, 3

- 4.5 %

Energy Efficiency 2, 3

up by 3.8 %

Proportion of Women in Senior Management

32 %

1 Currency- and portfolio-adjusted
2 Changes from 2016; 2016 figures restated
3 Bayer excluding Currenta

Latest Key Data

The interactive chart generator of Bayer AG gives an overview of the key financial and ecological data for the past five years. You can collate the given key data and years yourself in the form of tables, bar charts or line charts. Diagrams can be saved as graphics, tables as Excel documents.

Compare to Last Year